Moderna says patent ruling not to affect COVID-19 vaccine development


July 24 (Reuters) – Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.

An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna’s arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.

Moderna said the court’s ruling relates to actions it took in response to “longstanding aggressive posture” taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.

Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday. (Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)



Source link

The Usa Job

The USA Job is one of the top personal finance blog where you can find hundreds of best ideas and news to make money, save money, investment tips for everyone for better life.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.